•The field of Alzheimer’s research has been plagued with scandals, and despite receiving billions for research, it has failed to produce a treatment for the disease (conversely, proven treatments for the condition have already been discovered by independent researchers). FDA has recently had some very questionable drug approvals for Alzheimer’s drugs that were quite dangerous, exorbitantly expensive, and ineffective for treating the disease.

•A recent private industry conference (which sets the tone for the healthcare industry) had the current FDA commissioner as a featured speaker. This conference declared Alzheimer’s disease and obesity were two of the most profitable upcoming markets and encouraged investors to take advantage of the opportunities offered by these new medical franchises.

Note: this article was originally published on Mercola.com and has been revised since it’s initial publication.

Introduction

The pharmaceutical business model requires pharmaceuticals that are “effective” enough to somehow justify pushing them on patients but not effective enough to actually fix the issue the drug is prescribed for, thus requiring each patient to take the drug indefinitely. Furthermore, the larger the potential drug market is, the more aggressively the pharmaceutical industry will push to promote it to every available customer.

In some cases, such as for the dangerous and ineffective COVID-19 vaccines, this greed is so blatant even the general public can see it. Conversely, in other cases, it is typically invisible to any besides those directly affected by the drugs and their immediate family. Recently, for example, I reviewed the statin catastrophe after Aseem Malhotra on the Joe Rogan show brought the public’s attention to the danger and ineffectiveness of these drugs and how the same reprehensible forces we saw push the COVID-19 vaccines have been operating for decades within the cholesterol industry.

Although it’s challenging to claim any one class of drugs is the “worst, ” a good case can be made for psychiatric medications. In addition to the drugs being dangerously addictive and most of their “benefits” coming from doctored research data, they have some disturbing side effects. Beyond already tragic complications like fatal heart attacks (which happened to a close friend of mine), individuals on these drugs can become partially psychotic, and there are many tragic cases of suicides and homicides following their use. Unfortunately, because of just how large this market is, the industry and the FDA have gone to extreme lengths to cover up the harms of these drugs for decades, and business as usual continues in the psychiatric sector.

Note: much of this is difficult to believe, so I chronicled exactly what can now be proven happened with the antidepressants. I did this because what the FDA did back then is one of the closest precedents we have for understanding how the COVID-19 vaccines were handled and what to expect will happen in the future.

After I published an article summarizing the evidence for the psychotic, violent, and often deadly behaviors these drugs caused, Kim Witczak reached out to me to share her story. Soon after Zoloft entered the market, Kim’s husband Woody was unnecessarily put on the drug and, not long after, suddenly killed himself in a manner characteristic of a Zoloft suicide.

Kim decided the best thing she could do with this tragic situation was to work to prevent it from happening to anyone else. She had numerous successes and was instrumental in a black box warning for suicides being placed on SSRI antidepressants (something she believes would have been impossible to accomplish in today’s much more corrupt political climate). Due to her work, Kim became the consumer representative on the FDA’s Psychopharmacologic Drugs Advisory Committee and is frequently the only dissenting vote on unjustifiable drug approvals.

Note: This is analogous to how Ron Paul earned the nickname Dr. No during his time in Congress because he was frequently one of the only dissenting voices against unconstitutional legislation.

Kim periodically shares distressing things she observes with me:

Iam going to write about it, but I was once again the only no vote. This meeting was about using the antipsychotic Rexulti for an “unmet” need of Alzheimer’s Agitation indication. The data was minimal, and yet the death analysis was double the antipsychotic rate that the FDA calculated from a meta-analysis of other antipsychotics.

Anyway, the committee voted 9-1 to recommend approval for the “unmet” need. The reality is that the government has been cracking down on [dangerous and difficult to justify] antipsychotic use in nursing homes. They have noticed a rise of [likely fraudulent] schizophrenia diagnoses. So this will help the industry get their drugs covered [by insurance] and used in nursing homes. I told the FDA they need to watch the marketing and communication around this product to ensure the benefits are not overstated, and death downplayed.

It is so discouraging, and yet I know there are people like you that are out speaking the truth. But hey, at least I got the media to call me out for being the lone dissenting vote on this one!

Note: a much more detailed summary on the absolute absurdity of this approval written by Kim can be viewed here.

Recently, Kim shared something I believe has immense value for the entire public to know. However, to fully appreciate it, we must first take a quick detour into Alzheimer’s disease.

Alzheimer’s Research?

Alzheimer’s disease currently is one of the most devastating diseases in existence, both for the individual who experiences it (along with their family) and more broadly for society, as over 1% of global GDP is spent on caring for dementia (likewise in 2021 Alzheimer’s was estimated to cost the United States 355 billion dollars), and its cost has not stopped increasing. Because of this, Alzheimer’s disease is a “national research priority,” and in 2021, 3.1 billion was allotted for Alzheimer’s and dementia research. Yet despite over a century of research (amyloid was first identified as the cause of Alzheimer’s in 1906), cures for Alzheimer’s remain elusive.

The conventional view of Alzheimer’s is that…

Continue reading full story: What Are the Priorities of the Healthcare Industry?